drugset / Trial / NCT00673621

A Study Designed to Determine if the Pharmacokinetic Disposition of Inhaled Insulin Exposure is the Same for Asthmatics and Non-asthmatics

NCT00673621

Phase 1 Completed 30 enrolled Mannkind Corporation
Non-randomizedParallel-groupOpen-labelTreatment

Summary

This study will compare the rate and extent of absorption of TI Inhalation Powder in subjects with asthma and subjects with normal lung function. 24 eligible subjects will be enrolled into the treatment phase of the trial.

Timeline

Start
2008-05
Primary completion
2008-11
Completion
2008-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Insulin Protein / enzyme biologic 15 iu Inhaled
Subject Insulin Protein / enzyme biologic 30 iu Inhaled
Subject Insulin Protein / enzyme biologic 45 iu Inhaled
Background Salbutamol Unknown 200 ug Inhaled